Arne Thiermann, LL.M. (LSE) | Hamburg | Hogan Lovells

Arne Thiermann, LL.M. (LSE)

Partner Global Regulatory

Languages

English, German

Thiermann Arne

Arne Thiermann, LL.M. (LSE)
Thiermann Arne
  • Overview
  • Experience
  • Credentials
  • Insights and events
quote mark

"Reliable, high expertise in regulatory environment, high responsiveness.", client

Legal 500 Germany, 2021

National and international companies in the pharma, biotech and medical devices sector entrust Arne Thiermann with commercial contracts of strategic relevance as well as regulatory and compliance issues. Arne can assist you with his extensive experience in the drafting and negotiation of complex contracts in the life sciences sector. 

With a background in intellectual property law, Arne regularly handles licensing and development transactions in all stages of drug or device development. He further provides advice on strategic supply and manufacturing arrangements and helps you setting up R&D, marketing and distribution collaborations. You may also seek Arne's advice on regulatory issues in the context of researching, developing, marketing and distributing pharmaceutical products and medical devices.

Finally, Arne helps you marketing and advertising pharmaceutical products and medical devices in compliance with applicable laws and industry codes. He specifically assists life sciences clients on how to properly interact and collaborate with health care professionals. 

His goal is to show a solutions-oriented approach and deliver pragmatic solutions to his clients. Arne is listed as Name of the Next Generation for Industry focus: Healthcare in Legal 500 Germany in 2020 and 2021 and as often recommended lawyer for Pharmaceuticals and Medical Devices in JUVE handbook since 2016. Further he is acknowledged as noted practitioner for Life Sciences in Chambers Europe since 2015. Clients like working with him "because of the excellent work, the pragmatic approach, the high level of expertise and the trust that has grown over many years." (Legal 500 Germany, 2021) and praise him as "reliable, innovative and solution-oriented" (JUVE handbook, 2020/2021).

He regularly holds external and in-house presentations and seminars on regulatory topics and commercial contracts.

quote mark

"strong content, very good business understanding beyond legal issues", client

JUVE handbook, 2021/2022

Representative experience

Advising Merck & Co., Inc. on its worldwide license agreement with AiCuris GmbH & Co. KG regarding its HCMV portfolio.

Secondee to an international pharmaceutical company.

Advising a French nanomedicine company on a license agreement with a Taiwanese partner for the clinical development of its innovative product candidate in Asia-Pacific.

Advising a Germany-based worldwide leading medical devices company on the regulatory status of software and software systems.

Advising an international medical devices company on various regulatory, contractual, reimbursement and advertising law aspects.

Advising a leading German telecommunications provider on the acquisition of an online platform for the management of aid appliances.

Credentials

Education
  • LL.M., London School of Economics, 2007
  • Second State Exam in Law, Higher Regional Court of Munich, 2006
  • First State Exam in Law, LMU Munich (Ludwig-Maximilians-Universität München), 2004
Memberships
  • German Association for the Protection of Intellectual Property (GRUR)
  • Licensing Executives Society (LES)

Recognition

Often Recommended Lawyer for Pharmaceuticals and Medical Products

JUVE handbook

2016 – 2024
Leading lawyer for Life Sciences in Germany - Band 3

Chambers Europe

2022-2024
Leading lawyer for Life Sciences in Germany - Band 4

Chambers Europe

2015 – 2021
Next Generation Partner for Industry focus: Healthcare

Legal 500 Germany

2020-2024
Recommended Lawyer for Industry focus: Healthcare

Legal 500 Germany

2015-2017
Recommended Lawyer for Trade, Distribution, Logistics

Legal 500 Germany

2022-2024
Highly recommended lawyer for medical law for doctors, clinics, pharmaceutical companies and insurers

WirtschaftsWoche

2022